| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biochemistry, Saitama Cancer Research Institute, Ina-machi, Kitaadachi-gun, Saitama 362, Japan
The roles of two species of cytochrome P-450, the major cytochrome P-450 components of liver microsomes of phenobarbital-treated rats (PB-P-450) and 3-methylcholanthrenetreated rats (MC-P-448), were studied in the metabolism of benzo(a)pyrene in rat liver microsomes in vitro.
Benzo(a)pyrene was incubated with polychlorinated biphenyltreated rat liver microsomes, in which PB-P-450 and MC-P-448 constituted about 45 and 24% of the total cytochrome P-450, respectively. Then the metabolites were separated into those soluble in ethyl acetate and in water, and those covalently bound to protein. Using high-pressure liquid chromatography, the ethyl acetate-soluble metabolites were separated into three major groups, phenols, quinones, and dihydrodiols, including peaks of three unknown materials.
Addition of anti-MC-P-448 immunoglobulin to the reaction mixture completely inhibited the formation of all ethyl acetatesoluble metabolites. In contrast, anti-PB-P-450 immunoglobulin did not inhibit the formations of 4,5-dihydro-4,5-dihydroxybenzo(a)pyrene and 3-hydroxybenzo(a)pyrene; partially inhibited the formations of 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene, 9,10-dihydro-9,10-dihydroxybenzo(a)pyrene, and the three unknown materials; and caused 30 to 40% enhancement of the formations of 9-hydroxy-benzo(a)pyrene and benzo(a)pyrene-3,6-dione and 80% enhancement of that of benzo(a)pyrene-1,6-dione. Antibody against MC-P-448, but not against PB-P-450, also caused 75% inhibition of the formation of water-soluble metabolites and 85% inhibition of formation of benzo(a)pyrene metabolites covalently bound to protein.
These results show that MC-P-448 is important in the metabolism of benzo(a)pyrene.
1 This work was partly supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, Science and Culture.
2 To whom requests for reprints should be addressed.
Received 11/ 3/82. Accepted 5/ 5/83.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |